Patients treated with on dupilumab showed significant improvement in sustained BP remission compared with those on placebo.

Many skin conditions appear differently in melanated skin, leading to misdiagnosis and poor treatment. Understanding these ...

Nemluvio has received approval from the European Commission to treat moderate to severe atopic dermatitis and prurigo ...

The medication, also approved in the United States, is the first approved monoclonal antibody that specifically blocks the ...

Swiss dermatology company Galderma has announced two European approvals for Nemluvio (nemolizumab) to treat both atopic ...

The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for bullous pemphigoid by June 20, 2025.

Nemluvio is now the first approved monoclonal antibody that specifically targets interleukin-31 receptor alpha ...

A new medicine, Nenolizumab, has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) to treat two skin conditions ...

Galderma today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency and Swissmedi ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on positive pivotal results demonstrat ...

UK MHRA grants marketing approval to Galderma’s nemolizumab to treat prurigo nodularis and atopic dermatitis: United Kingdom Tuesday, February 18, 2025, 14:00 Hrs [IST] The Medi ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...